Germ-line BRCA1/2 testing recommended in ovarian cancer

Share this article:
Germ-Line <i>BRCA1/2</i> Testing Recommended in Ovarian Cancer
Germ-Line <i>BRCA1/2</i> Testing Recommended in Ovarian Cancer

(HealthDay News) -- Due to the potential survival and treatment response implications of BRCA mutation status, it is recommended that germ-line BRCA1/2 testing be offered to all women diagnosed with nonmucinous ovarian carcinoma, regardless of family history, according to research published online June 18 in the Journal of Clinical Oncology.

To investigate the impact of germ-line BRCA1 and BRCA2 mutations in ovarian cancer, Kathryn Alsop, of the Peter MacCallum Cancer Centre in East Melbourne, Australia, and colleagues screened 1,001 women with nonmucinous ovarian carcinomas enrolled in a case-control study for germ-line point mutations and large deletions in BRCA1 and BRCA2 genes.

The researchers found that 14.1 percent of patients exhibited BRCA1/2 germ-line mutations. Of these, 16.6 percent had serous cancer and 44 percent reported no family history of either breast or ovarian cancer. Compared with women without germ-line mutations, patients with germ-line mutations had improved rates of progression-free and overall survival and tended to respond to platin and nonplatin-based regimens in the relapse setting. Somatic BRCA1/2 mutations were more likely to be found in mutation-negative patients who responded to multiple cycles of platin-based treatment.

"Our findings suggest changes in the guidelines for genetic testing of all invasive ovarian cancer patients, indicate that the measurement of BRCA status should be explicitly integrated into future clinical trial designs as a major stratification factor, and declare BRCA status is now ready to be included in the clinical management of women with ovarian cancer," the authors write.

Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Cancer 'vaccine' for advanced disease shows early progress

Cancer 'vaccine' for advanced disease shows early progress

Early progress has been made in developing a treatment that might one day help the immune system defend itself against cancer, but research is still in preliminary stages.

Clinician-patient relationship tied to health care outcomes

Clinician-patient relationship tied to health care outcomes

Meta-analysis of 13 randomized controlled trials shows small but significant effect from the patient-clinician relationship.

Patients see sharp increase in price of specialty drugs

Patients see sharp increase in price of specialty ...

Many Americans paying less for prescription drugs, but some are having to deal with sharp rises in cost of specialty meds.